Thymosins can enhance body immunity and are mainly used in the treatment of hepatitis and tumors. Thymosins mainly include Thymosin, Thymopentin and Thymosin α1. Thymosin α1 is a high-end thymosin. Clinical trials suggest it may be useful in cystic fibrosis, septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, TB, severe acute respiratory syndrome, and lung infections in critically ill patients., and for chronic hepatitis B. It also has been studied for possible use in treating cancer (eg with chemotherapy).

The global Thymosin α1 market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Thymosin α1 volume and value at global level, regional level and company level. From a global perspective, this report represents overall Thymosin α1 market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Abbiotec
SciClone Pharmaceuticals
Shanghai Soho-Yiming Pharmaceuticals
Hainan Zhonghe Pharmaceutical
Hainan Shuangcheng Pharmaceuticals
Hybio Pharmaceutical
Suzhou Tianma Pharma Group Tianji Bio-pharmaceutical
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Freeze-dried Powder
Injection

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies